| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
TRPA1 (Transient Receptor Potential Ankyrin 1) ion channel. Moringin is a selective TRPA1 agonist with an EC50 of 3.14 uM. It does not activate or only very weakly activates the vanilloid channels TRPV1, TRPV2, TRPV3, TRPV4, and the melastatin cooling receptor TRPM8.
|
|---|---|
| ln Vitro |
Moringin (16.4 µM; 24-72 hours) dramatically inhibited the development of SH-SY5Y human neuroblastoma cells in a concentration- and time-dependent manner [2]. In SH-SY5Y cells, moringin (1.64-8.2 μM; 24 h) enhances the transcript and protein levels of p53, p21, and Bax expression. Moringin triggers the intrinsic apoptotic cascade by dramatically upregulating the expression of the caspase 3/9 gene and facilitating its cleavage [2]. NF-κB's nuclear translocation is inhibited by moringin [2].
Moringin activates TRPA1 channels in a concentration-dependent manner with an EC50 of 3.14 uM in calcium imaging assays using TRPA1-expressing cells. It also exhibits hypoglycemic activity and antioxidant properties in various in vitro assays. |
| ln Vivo |
Pretreatment with Moringin (10 mg/kg; i.p.; once daily for 5 weeks) normalized the aberrant Wnt-β-catenin pathway in mice with experimental autoimmune encephalomyelitis (EAE). This resulted in GSK3β inhibition and β-catenin upregulatory activity, which in turn regulated T cell activation (CD4 and FoxP3) and inhibited major inflammatory mediators (IL-1β, IL-6, and COX2) by activating PPARγ. In EAE mice, moringa upregulates Nrf2 expression, an antioxidant [3].
No published in vivo animal efficacy studies specific to moringin‘s primary pharmacology are available. However, in animal models of diabetes and inflammation, Moringa oleifera extracts (which contain moringin) have shown beneficial effects on blood glucose and inflammatory markers, but the specific contribution of moringin requires further validation. |
| Enzyme Assay |
TRPA1-expressing HEK293 cells are loaded with a calcium-sensitive fluorescent dye (e.g., Fluo-4 AM) and seeded into 384-well plates. Cells are treated with increasing concentrations of moringin (0.1-100 uM) while fluorescence is recorded. EC50 values are calculated by analyzing the peak fluorescence response. Positive controls include known TRPA1 agonists like AITC or cinnamaldehyde.
|
| Cell Assay |
Human neuroblastoma cells (SH-SY5Y) are seeded and treated with moringin (1-100 uM) for 24-48 hours. Cell viability is assessed by MTT assay. Intracellular calcium levels are measured using Fluo-4 AM staining. For TRPA1 silencing, cells are pretreated with TRPA1-specific siRNA before moringin addition to confirm target specificity. Supernatants are collected for inflammatory cytokine measurement.
|
| Animal Protocol |
No specific in vivo animal experimental protocols for moringin are available in the literature. In general, moringin is dissolved in a suitable vehicle (e.g., PBS with 10% DMSO) and administered to rodents via intraperitoneal injection (5-20 mg/kg) or oral gavage (50-100 mg/kg). Blood glucose measurements and tissue collection (pancreas, liver, fat) are performed at specified time points.
|
| ADME/Pharmacokinetics |
No detailed pharmacokinetic data are available for moringin. Its oral bioavailability is expected to be low due to extensive first-pass metabolism, as is common with isothiocyanates, which are conjugated by glutathione-S-transferases. The half-life in circulation is likely short (minutes to hours). May be a substrate for efflux transporters.
|
| Toxicity/Toxicokinetics |
No specific toxicity data are available for moringin in the literature. As a naturally occurring isothiocyanate found in dietary moringa, it is expected to have a low toxicity profile at moderate doses. However, at high concentrations, isothiocyanates can cause cellular stress and DNA damage.
|
| References |
|
| Additional Infomation |
According to reports, Moringa contains α-L-mannopyranoside and 4-(methyl isothiocyanate)phenyl-6-deoxy-, and there is relevant data.
Other information: Moringin is also known as 4-[(alpha-L-rhamnosyloxy)benzyl]isothiocyanate. It is the primary bioactive isothiocyanate in Moringa oleifera seeds. As a natural product, it is being investigated for potential therapeutic applications in pain, inflammation, and metabolic disorders, but it has not yet advanced to clinical trials. Not FDA-approved. |
| Molecular Formula |
C14H17NO5S
|
|---|---|
| Molecular Weight |
311.35
|
| Exact Mass |
311.083
|
| CAS # |
73255-40-0
|
| PubChem CID |
153557
|
| Appearance |
White to light yellow solid powder
|
| LogP |
0.495
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
21
|
| Complexity |
382
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC2=CC=C(C=C2)CN=C=S)O)O)O
|
| InChi Key |
QAZIHHJTZPNRCM-CNJBRALLSA-N
|
| InChi Code |
InChI=1S/C14H17NO5S/c1-8-11(16)12(17)13(18)14(19-8)20-10-4-2-9(3-5-10)6-15-7-21/h2-5,8,11-14,16-18H,6H2,1H3/t8-,11-,12+,13+,14-/m0/s1
|
| Chemical Name |
(2S,3R,4R,5R,6S)-2-[4-(isothiocyanatomethyl)phenoxy]-6-methyloxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2118 mL | 16.0591 mL | 32.1182 mL | |
| 5 mM | 0.6424 mL | 3.2118 mL | 6.4236 mL | |
| 10 mM | 0.3212 mL | 1.6059 mL | 3.2118 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
